EXHIBIT 4

EXHIBIT 4

Vanderbilt University v. ICOS Corporation, No. 05-506 SLR

Plaintiff's Trial Exhibits

	Bates Number	Date	Description	Identified	Objection	Admitted
1			Jackie D. Corbin, Ph.D. Curriculum Vitae		NP;802;DI	
2			Sharron Francis, Ph.D. Curriculum Vitae		NP;802;DI	
3			Sekhar R. Konjeti, Ph.D. Curriculum Vitae		NP;802;DI	
4	VU000001-92		Vanderbilt University Faculty Manual		602;802;901	
5a	VU000093-99		Vanderbilt University Faculty Manual Ch. 4		602;802;901	
5b	VU000100-101		Vanderbilt University Faculty Manual Ch. 5		602;802;901	
6	VU000182-183		Assignment of Jackie Corbin		DI;LP;802	
7	VU000184-185		Assignment of Sekhar Konjeti		DI;LP;802	
8	VU000186-187		Assignment of Sharron Francis		DI;LP;802	
9	VK-05391		Slide: Putative Mechanism for cGMP and cAMP in Smooth Muscle Relaxation		106;403;802; 901	
10	VK-07584		Slide: Modification of cGMP at the 8-Position		106;403;802; 901	
11	VK-05443		Slide: Proposed Structure of cGMP-Dependent Protein Kinase		106;403;802; 901	
12	VC-006519		Slide: A cGMP-Binding Site Model for cGMP-Dependent Protein Kinase		106;403;901; 802	

	Bates Number	Date	Description	Identified	Objection	Admitted
13	VC-006540		Slide: Modification of cGMP at the 8-Position		106;403;901; 802	
14	VC-006536		Slide: cGMP Modifications		106;403;901; 802	
15	VK-07582		Slide: Modification of cGMP at Both the 1, 2-And 8-Positions		106;403;802; 901	
16	VK-05453		Slide: ß-PHENYL-1,N²-ETHENO-cGMP (PET-cGMP)		106;403;802; 901	
17	VC-006537		Slide: 8-Bromo-Cgmp		106;403;802; 901	
18	VC-006541		Slide: ß-PHENYL-1,N²-ETHENO-cGMP (PET-cGMP)		106;403;802; 901	
19	VK-05405		Slide: Hydroxy Phenylthio-cGMP		106;403;802; 901	
20	VK-05477		Slide: Structure Similarities Between cGMP and a Phosphodiesterase Inhibitor		106;403;802; 901	
21	VK-07580		Slide: Molecular Structures of cGMP and Zaprinast		106;403;802; 901	
22	VK-05467		Slide: Possible Modifications of Xanthine Nucleus Required for PDE Inhibition		106;403;802; 901	
23	VK-05503		Slide: Synthesis of 8-phenylthio-IBMX and 8-phenylamino-IBMX analogues		106;403;802; 901	
24	VK-05495		Slide: Synthesis of 8-styryl-IBMX and 8-allcyclylmethyl-IBMX analogues		106;403;802; 901	
25		1/1/80	Francis, S.H., Lincoln, T.M., and Corbin, J.D. (1980) Characterization of a Novel cGMP Binding Protein from Rat Lung. J. BioI. Chem 255:620-626		NP;402;802	
26		1/1/85	Francis, S.H. (1985) Effectors of rat lung cGMP binding protein phosphodiesterase. Current Topics in Cellular Regulation 26:247-262		NP;402;802	

	Bates Number	Date	Description	Identified	Objection	Admitted
27	VF000001-143	4/24/85	Francis Notebook		106;402;403; 802;901	
28	VC004466-784	9/23/86	Withdrawn			
29	VC001431-1436	1/25/88	Francis, S.H., Noblett, B, Todd, B.W., Wells, J.N., and Corbin, J.D., Relaxation of Vascular and Tracheal Smooth Muscle by Cyclic Nucleotide Analogs that Preferentially Activate Purified cGMP-Dependent Protein Kinase, Mole. Pharmacol., 34: 506		402;802;901	
30	VC004952-5270	4/1/88	Withdrawn			
31		1/1/89	Gillespie, P.G., and Beavo, J.A. (1989) Inhibition and stimulation of photoreceptor phosphodiesterases by dipyridamole and M&B 22,948, Mol. Pharmacol. 36: 773-81 (Francis Rept. Exh. 5)		602;802;901	
32	VC000018	12/16/88	Glaxo Cardiovascular Discovery Grants Application		402;802;901	
33	VC006427-6453	1/1/89	1989 Calendar		402;403;901; 802	
34	VC000013-14	03/04/89	Letter from Don F. Kirksey, Ph.D. of Glaxo to Jackie D. Corbin, Ph.D. enclosing list of Discovery Grant Award Awardees		106;402; 403; 802;901	
35	VM-0567-608	7/1/89	Glaxo Cardiovascular Discovery Grants Research Agreement		106;403;802	
36	VC000061	10/27/89	Letter from Don F. Kirksey, Ph.D. of Glaxo to Jackie D. Corbin, Ph.D.		802;901	
37	VC-000184	11/1/89	Corbin's schedule including presentation for November 1		802;901	
38	VC006331-332	1/1/90	1990 Calendar		402;403;901; 802	

	Bates Number	Date	Description	Identified	Objection	Admitted
39		1/1/90	Thomas, M.K., Francis, S.H., and Corbin, J.D. (1990) Substrate- And Kinase-Directed Regulation Of Phosphorylation Of A Cgmp-Binding Phosphodiesterase By Cgmp. J. BioI. Chem. 265: 14971-14978		NP;402;802	
40	VK000252-461	1/6/90	Konjeti Notebook		802;901	
41	VC000068	3/17/90	List of Attendees at March 1990 Glaxo Discovery Conference		802;901	
42	VC000069-70	3/30/90	Letter from Jackie D. Corbin, Ph.D to Don F. Kirksey, Ph.D. of Glaxo		802;901	
43	ICOS001655-661	4/11/90	Thomas, M.K., Francis, S.H., and Corbin, J.D. (1990) Characterization Of A Purified Bovine Lung Cgmp-Binding Cgmp Phosphodiesterase. J. BioI. Chem. 265:14964-14970.		802;901	
44	VC000078-80	6/90	Cardiovascular Discovery Grant 1989-1990 Annual Report. Project Title - Relaxation of Vascular Smooth Muscle by cGMP Analogs		403;V067;802;901	
45	VC000074	10/23/90	Letter from Don F. Kirksey, Ph.D. of Glaxo to Jackie D. Corbin, Ph.D.		802;901	
46	VC000075-77	11/2/90	Letter from Jackie D. Corbin, Ph.D to Don F. Kirksey, Ph.D. of Glaxo enclosing updated progress report		802;901	
47	VC-00081-82	11/28/90	Letter from Corbin (Vanderbilt) to Kirksey enclosing a copy of the abstract which is to be published in the FASEB Abstracts		402;802;901	
48	VC-06313-330	1/1/91	1991 Calendar			
49	VC000085	1/17/91	Letter from Don F. Kirksey, Ph.D. of Glaxo to Jackie D. Corbin, Ph.D.		402;403;802;901	
50	VC006176	2/1/91	Withdrawn			
51	GLAX15561-678	3/18/91	Glaxo Research Laboratories Glaxo Inc. Cardiovascular Status Report			

	Bates Number	Date	Description	Identified	Objection	Admitted
52	GLAX03641-689	3/18/91	Glaxo Research Laboratories Glaxo, Inc. Cardiovascular Status Report			
53	VC-000905	3/18/91	Glaxo Discovery Conference, Pittsboro, NC Schedule for March 18th		802;901	
54	VK000985-1165	3/19/91	Konjeti Notebook		802;901	
55	VC000086-89	3/28/91	Letter from Jackie D. Corbin, Ph.D. to David Levy of Glaxo		802;901	
56	VC-00135-153	4/18/91	Relaxation of Pig Coronary Arteries By New And Potent cGMP Analog That Selectively Activate Type Ia Compared to Type Ib cGMP-Defendant Protein Kinases, by Sekhar, Hatchett, Shabb, Francis, Wells and Corbin		403;802;901	
57	VM-00702-745	4/18/91	Letter dated from David J. Levy (Glaxo) to Jackie D. Corbin, Ph.D. regarding a literature search for the compounds listed in Corbin's letter		106;802;901	
58	GLAX 15734-15771	6/17/91	Report of Jorge Kirilovsky and his visit to Glaxo USA			
58A	VU-000466-483	6/17/91	English Translation of GLAX15734-15771		LP;402;602; 802	
59	VC000158	5/29/91	Letter from Ronald E. Keeney, M.D. and Don F. Kirksey, Ph.D. of Glaxo to Jackie D. Corbin, Ph.D.		802;901	
59A	VC000156-157	5/29/91	Letter from Dr, M.W. Elves of Glaxo to Jackie D. Corbin, Ph.D.		802;901	
60	GLAX25372	6/91	Handwritten notes		106;402;602; 802; 901	
60A	VU000188-189	6/91	English translation of GLAX 25372		LP;602;802	
61	GLAX00487-501	6/3/91	Project Phosphodiesterase (PDE) Compte-rendu de la reunion du 3 Juin 1991			
62	VU000190-193	6/3/91	English translation of GLAX 00487-88		LP;602;802; 901	

	Bates Number	Date	Description	Identified	Objection	Admitted
63	GLAX10263-271	6/11/91	International Research Strategy Meeting Minutes of the Meeting Held at Glaxo Group Research, Ware, Hertfordshire			
64	GLAX02203-2271	6/14/91	Cinquin Notebook, dated 6/14/91-8/23/91			
65	VC000159	6/20/91	Letter from Ronald E. Keeney, M.D. of Glaxo to Jackie D. Corbin, Ph.D.		802;901	
66	VC0001595	6/24/91	Withdrawn			
67	VC000161-163	6/27/91	Cardiovascular Discovery Grant 1990-1991 Annual Report		403;802;901	
68	GLAX00502-516	7/9/91	Projet PDE Compte-rendu de la reunion du 9 Juillet 1991 (AC, BD, DC, FH, PG)			
69	VU000194-197	7/9/91	English translation of GLAX 00502-04		LP;802;901	
70	VC000164	7/11/91	Letter from Ronald Keeney, M.D. of Glaxo to Jackie D. Corbin, Ph.D.		802;901	
71	VC000165	7/24/91	Letter from Jackie D. Corbin, Ph.D. to Dr. Michael W. Elves of Glaxo		802;901	
72	GLAX11649-660	9/91	Withdrawn			
73	VC006182-183	9/25/91	Withdrawn			
74	GLAX00574	9/27/91	Reunion P.D.E. Mercredi 9 Octobre 1991, 10 H Ordre Du Jour			
75	GLAX16596	9/27/91	Compound Data Card for AH19041XX			
76	GLAX15773-802	10/9/91	PDE Project Meeting Agenda and Minutes			
77	VU000198-201	10/9/91	English translation of GLAX 15773-75		LP;802;901	

	Bates Number	Date	Description	Identified	Objection	Admitted
78	GLAX15803-809	9/91	Davey, D.D., Erhardt, P.W., Cantor, E.H., Greenberg, S.S., Ingebretsen, W.R. and Wiggins, J., Novel Compounds Possessing Potent cAMP and cGMP Phosphodiesterase Activity. Synthesis and Cardiovascular Effects of a Series of Imidazo [1,2] quinoxalinones and Imidazo[1,5]quinoxalinones and Their Aza Analogues, J.Med. Chem. 1991, 34, 2671-2677.			
79	GLAX14240	10/18/91	ISIS Print: AH18975, AH19041			
80	GLAX13938	10/18/91	ISIS Print: AH19041			
81	VC000171	10/30/91	Letter from Jackie D. Corbin, Ph.D. to Fiona Roberts of Glaxo		802;901	
82	GLAX15450	10/30/91	ISIS Print: GR35028X, GR35112X			
83	VC000173	10/31/91	Facsimile from Fiona Roberts of Glaxo to Jackie D. Corbin, Ph.D.		802;901	
84	GLAX14402	10/31/91	ISIS Print: GF148445X, GF148447X			
85	GLAX14403	10/31/91	ISIS Print: GF148448X, GF148450X			
86	GLAX14404	10/31/91	ISIS Print GF148451X, 148452X			
87	VC000182-183	11/1/91	Letter dated 11/1/91 from Jackie Corbin (Vanderbilt) to Ken Ferguson (ICOS)		402;403;802; 901	
88	VK001641-762	11/2/91	Konjeti Notebook		402;802;901	
89	VC-000185	11/12/91	Letter from Jackie Corbin to Jackie Schrago		402;802;901	
90	GLAX14399	11/19/91	ISIS Print: GF14598X, GF147123X			
91	GLAX14400	11/19/91	ISIS Print: GF147124X, GF147888X			
92	GLAX14405	11/19/91	ISIS Print: GF148455A, GF149426X			
93	GLAX14406	11/19/91	ISIS Print: GF149427X, GF149428X			

	Bates Number	Date	Description	Identified	Objection	Admitted
94	GLAX14408	11/19/91	ISIS Print: GF149965X, GF150338X			
95	VC000175-178	11/19/91	Facsimile from Fiona Roberts of Glaxo to Jackie D. Corbin, Ph.D. enclosing Proposal Form and Conditions for the Provision of Compounds to Outside Investigators		602;802;901	
96	GLAX10746-749	11/20/91	Memorandum from Dr. Barry Ross of Glaxo to Dr. Barry Ross of Glaxo			
97	GLAX14410	12/4/91	ISIS Print: GF151202A, GF151203X			
98	GLAX14411	12/4/91	ISIS Print: GF151205X, GF151292X			
99	GLAX14412	12/4/91	ISIS Print: GF151294A, GF151297X			
100	GLAX15825-840	12/9/91	PDE Project Meeting Agenda and Minutes			
101		12/9/91	Sekhar, RR, Hatchett, RJ, Shabb, JB, Wolfe, L, Francis,SH, Wells, JN, Jastorff, B, Butt, E, Chakinala, MM,and Corbin, J.D. (1992) Relaxation of pig coronary arteries by new and potent cGMP analogs that selectively activate type I-alpha, compared with type I-beta, cGMP-dependent protein kinase. Molecular Pharmacolology. 42, 103-108		NP;402	
102	GLAX14415	12/13/91	ISIS Print: GF151640X, GF151831X			
103	GLAX14416	12/13/91	ISIS Print: GF151833X, GF152508X			
104	VC-000224	12/26/91	Withdrawn			
105	VC006211	12/31/91	Corbin notes regarding telephone call with Barry Ross		106;402;602; 802;901	
106	VC000813-821	1/1/92	Thomas, M.K., et al. , Partial Mapping of Cyclci Nucleotide Sites and Studies of Regulatory Mechanisms of Phosphodiesterases Using Cyclic Nucleotide Analogues, Advances in Second Messenger and Phosphoprotein Research, Vol. 25.		802;901	

	Bates Number	Date	Description	Identified	Objection	Admitted
107	VC000225-227	1/3/92	Letter from Jackie D. Corbin, Ph.D. to Dr. Barry Ross of Glaxo			
108	VC000084	1/6/92	Facsimile from Jackie D. Corbin, Ph.D. to Heidi Edward of Glaxo			
109	VC-000228	1/6/92	Facsimile from Heidi Edward of Glaxo to Jackie D. Corbin, Ph.D.		402;802;901	
110	GLAX15841-869	1/13/92	PDE Project Meeting Agenda and Minutes			
111	VC000232	1/20/92	Facsimile from Jackie D. Corbin, Ph.D. to Heidi Edward of Glaxo		802;901	
112	VC000230	1/20/92	Facsimile from Heidi Edward of Glaxo to Jackie D. Corbin, Ph.D.			
113	VC000234	1/23/92	Letter from Jackie D. Corbin, Ph.D. to Heidi Edward of Glaxo		802;901	
114	ICOS001267	2/01/92	Handwritten notes		106;602;802; 901	
115	GLAX17645	2/11/92	Compound Data Card: GR35028			
116	GLAX15870-898	2/21/92	Project PDE Meeting Agenda and Minutes			
117	VC000249-254	2/24/92	Proposal for a Glaxo/Corbin Research Project," Synthesizing cGNP Analogs and Phosphodiesterase Inhibitors to Probe the Mechanism and Roles of Smooth Muscle Protein Kinases and Phosphodiesterases		802;901	
118	VC000248	2/24/92	Letter from Jackie D. Corbin, Ph.D. to Dr. Barry Ross of Glaxo		802;901	
119		3/5/92	Shabb, JB, and Corbin, JD. (1992) Cyclic nucleotide-binding domains in proteins having diverse functions. J. BioI. Chern. 267, 5723-5726		NP;402	
120	GLAX22474-689	4/2/92	Research Notebook B148 Florence Godard			

	Bates Number	Date	Description	Identified	Objection	Admitted
121	GLAX13186, 01999-02004	4/8/92	Memorandum from Dr. Barry Ross of Glaxo to Dr. R. Labaudiniere, et. al. of Glaxo enclosing Vanderbilt research proposal			
122	GLAX25937-947	4/9/92	PDE V Project Status Report to the Cardiovascular Research Management Committee			
123	GLAX25733-741	4/9/92	Cardiovascular Research Management Committee Meeting minutes			
124	VC007169	4/13/92	Letter from Jackie D. Corbin, Ph.D. to Barry Ross, Ph.D.		106;901;802	
125	GLAX15972-975	4/16/92	Project PDE Meeting Agenda and Minutes			
126	VU000202-203	4/16/92	English translation of Exhibit 83 [GLAX15972-75]		LP;802;901	
127	GLAX15913-943	4/21/92	Project PDE Meeting Agenda and Minutes			
128	VU000204-207	4/21/92	English translation of GLAX 15913-15		LP;802;901	
129	GLAX14477	4/22/92	ISIS Print: GF160167X, GF160168X			
130	GLAX14478	4/22/92	ISIS Print: GF160171X, GF160175X			
131	GLAX14479	4/22/92	ISIS Print: GF160178X, GF160179X			
132	GLAX14476	4/22/92	ISIS Print GF159818X, GF159826X			
133	GLAX14480	4/22/92	ISIS Print GF160180X, GF160375X			
134	GLAX15515	4/23/92	ISIS Print: GR76505X, GR77123A			
135	GLAX15526	4/23/92	ISIS Print: GR82778X, GR83104A			
136	GLAX15401	4/23/92	ISIS Print: GR143577X, GR143657X			
137	GLAX15460	4/23/92	ISIS Print: GR37540X, GR37913X			
138	GLAX15495	4/23/92	ISIS Print: GR65357A, GR66022X			

	Bates Number	Date	Description	Identified	Objection	Admitted
139	GLAX14251	4/23/92	ISIS Print: AH20899XX, AH20905XX			
140	GLAX15438	4/23/92	ISIS Print: GR30040X, GR30075A			
141	GLAX15458	4/23/92	ISIS Print: GR37019X, GR37113A			
142	GLAX14271	4/23/92	ISIS Print: AH22608X, AH22815X			
143	GLAX15274	4/23/92	ISIS Print: GI144264A, GI147404X			
144	GLAX15486	4/23/92	ISIS Print: GR60781X, GR60805A			
145	GLAX15452	4/23/92	ISIS Print: GR35223A, GR35273X			
146	GLAX14304	4/23/92	ISIS Print: AH4213, AH4217			
147	GLAX14394	4/23/92	ISIS Print: GI199435X, GI199546A			
148	GLAX15278	4/23/92	ISIS Print: GI199435X, GR119668A			
149	GLAX15457	4/23/92	ISIS Print: GR36621X, GR36822X			
150	GLAX15459	4/23/92	ISIS Print GR37277X, GR37539X			
151	GLAX15461	4/23/92	ISIS Print GR38053X, GR39500X			
152	GLAX15491	4/23/92	ISIS Print GR62719X, GR65184A,			
153	GLAX15494	4/23/92	ISIS Print GR64406X, GR64544X			
154	GLAX01450-475	4/24/92	PDE V Inhibitors Project Annual Report for the Year Ending 30/04/92			
155	VC005614-6039	4/29/92	Francis Notebook		802;901	
156	VC-000256	4/30/92	Letter from Dr. Barry Ross of Glaxo to Jackie D. Corbin, Ph.D.		802;901	
157	GLAX25154	5/1/92	Abstract – Relaxant effects of beta-carbolines on rat aortic rings 5/1/92			
158	GLAX00484; GLAX00271-274	5/13/92	PDE Strategy Meeting Minutes			
159	VU000208-212	5/13/92	English translation of GLAX 00271-74		LP;602;802	

	Bates Number	Date	Description	Identified	Objection	Admitted
160	GLAX10352-GLAX10360	5/14/92	Cardiovascular Diseases Research Management Committee PDE V Project Status Report			
161	VC004014-187	5/30/92	Withdrawn			
162	GLAX13120	6/3/92	Research Strategy Meeting Agenda			
163	VC000259, 261-74	6/8/92	Letter from Jackie D. Corbint, Ph.D. to Dr. M.W. E.lves of Glaxo		106;901;802	
164	GLAX10361-375	6/11/92	Cardiovascular Diseases Research Management Committee PDE V Project Status Report			
165	VC-000257	6/14/92	Letter from Elves (Glaxo) to Jadkie D. Corbin, Ph.D.		802;901	
166	GLAX15985-16022	6/23/92	Projet PDE Meeting Agenda and Minutes			
167		6/25/92	List of Analogues "Bzd"		602;802;901; DI	
168	VC-000711-725	7/6/92	Letter from Elves (Glaxo) to Jackie D. Corbin, Ph.D enclosing draft research agreement		802;901	
169	GLAX14341	7/7/92	ISIS Print: CCI17953, CCI19232			
170	GLAX14347	7/7/92	ISIS Print: CCI23002A, CCI23005			
171	GLAX14348	7/7/92	ISIS Print: CCI23006, CCI23009			
172	GLAX14349	7/7/92	ISIS Print: CCI23020, CCI23026			
173	GLAX15440	7/7/92	ISIS Print: GR30338A, GR30413X			
174	GLAX15533	7/7/92	ISIS Print: GR89208X, GR89229A			
175	VK001166-1359	7/17/92	Konjeti Research Notebook		402;802;901	
176	GLAX01148-151	7/24/92	Excerpt from Pascal Grondin Research Notebook			
177	VU000213-218	7/28/92	English translation of GLAX 16025-29		LP;802	

	Bates Number	Date	Description	Identified	Objection	Admitted
178	GLAX16025-82	7/28/92	Projet PDE Meeting Agenda and Minutes			
179	VC000279	7/31/92	Letter from Dr. B.C. Ross of Glaxo to Jackie D. Corbin, Ph.D.		802;901	
180	VC000278	8/3/92	Facsimile from Jackie D. Corbin, Ph.D. to Dr. B. C. Ross of Glaxo		802;901	
181	GLAX00853-855	8/6/92	Letter from Dr. F. Hyafil of Glaxo to Jackie D. Corbin, Ph.D.			
182	VC000307	8/10/92	Letter from Jackie D. Corbin, Ph.D. to Dr. F. Hyafil of Glaxo		403;802;901	
183	VC000316	8/14/92	Letter from Jackie D. Corbin, Ph.D. to Dr. F. Hyafil of Glaxo		402;203;802; 901	
184	VC000311	8/14/92	Facsimile from Dr. F. Hyafil of Glaxo to Jackie D. Corbin, Ph.D.			
185	VC000323	8/19/92	Letter from Dr. GM Drew of Glaxo to Jackie D. Corbin, Ph.D.		802;901	
186	VK000032-33	8/20/92	Facsimile from Jackie D. Corbin, Ph.D. to Dr. GM Drew of Glaxo		402;802;901	
187	VC000322	8/28/92	Facsimile from Dr. GM Drew of Glaxo to Jackie D. Corbin, Ph.D.		802;901	
187A	VC000315	9/3/92	Letter from Jackie D. Corbin, Ph.D. to Isabelle Couleon of Glaxo		403;802;901	
188	GLAX318, 309-317	9/9/92	Projet PDE Meeting Agenda and Minutes			
189	VU000219-232	9/9/92	English translation of GLAX318, 309-317		LP;802;901	
190	GLAX13096-105	9/11/92	Cardiovascular Diseases Research Management Committee PDE Project Status Report			
191	GLAX07600-806	9/22/92	Narina Dodic Research Notebook			
192	GLAX16135-149	9/29/92	Hyafil Slide Presentation			
193	GLAX25343	9/30/92	Data provided to Hyafil by Konjeti			

	Bates Number	Date	Description	Identified	Objection	Admitted
194	GLAX25338	9/30/92	Handwritten notes			
195	ICOS001289-300	10/1/92	Progress In the Chemistry and Biology of PDE Inhibitors		602;802;901	
196	GLAX03622-628	10/5/92	Annie Penfornis Notebook, dated 10/5/92-11/12/93			
197	GLAX18476	10/6/92	Compound Data Card GF173320X			
198	GLAX18474	10/6/92	Compound Data Card GF173218X			
199	GLAX18475	10/6/92	Compound Data Card GF173219X			
200	GLAX17638	10/6/92	Compound Data Card GI 120547X			
201	GLAX02005	10/7/92	Letter from Dr. F. Hyafil of Glaxo to Jackie D. Corbin, Ph.D.			
202	GLAX10422-430	10/8/92	Cardiovascular Diseases Research Management Committee PDE V Project Status Report			
203	GLAX14605	10/14/92	ISIS Print: GF173220X, GF173317X			
204	GLAX14607	10/15/92	ISIS Print: GF173320X, GF173321X			
205	VK000039-41	10/21/92	Letter from Dr. GM Drew of Glaxo to Sekhar R. Konjeti		802;901	
206	VC-000336-338	10/27/92	Facsimile from Jackie D. Corbin, Ph.D. to Pascal Grondin of Glaxo			
207	GLAX16254-328	10/28/92	Projet PDE Meeting Minutes			
208	VU000233-308	10/28/92	English translation of GLAX 16254-16328		LP;802	
209	GLAX14629	11/4/92	ISIS Print: GF175353X, GF175402X			
210	GLAX15255	11/5/92	ISIS Print: GI120546X, GI120547X			
211	VC000325-33	11/14/92	Letter from Michael Borun, Esq. of Marshall, O'Toole, Gerstein, Murray & Bicknell to Judith Woods, Esq. of ICOS		402;403;602; 802;901	

	Bates Number	Date	Description	Identified	Objection	Admitted
212	GLAX14604	11/15/92	ISIS Print: GF173218X, GF173219X			
213	VK000042	11/19/92	Letter from Sekhar R. Konjeti to Dr. GM Drew of Glaxo		802;901	
214	GLAX16196-200, 16212, 16215	11/26/92	Projet PDE Meeting Agenda and Minutes			
215	GLAX14664	11/27/92	ISIS Print: GF177704X, GF177705X			
216	VC000366-386	11/30/92	Letter from Fiona Roberts of Glaxo to Jackie D. Corbin, Ph.D. enclosing research agreement and check		802;901	
217	VC000387-388		Chemical depictions of five compounds with handwritten notes		106;602;802; 901	
218	VC000390		Computer generated graph with handwritten notes		106;602;802; 901	
219	GLAX15366	12/02/92	ISIS Print: GR121867X, GR122058X			
220	GLAX17220	12/04/92	Compound Data Card GF178533X			
221	GLAX17221	12/04/92	Compound Data Card GF178534X			
222	GLAX14676	12/09/92	ISIS Print: GF178533X, GF178534X			
223	GLAX00860-862	12/11/92	Letter from Pascal Grondin of Glaxo to Jackie D. Corbin, Ph.D.			
224	VC000393-394	12/15/92	Letter from Jackie D. Corbin, Ph.D. to Dr. Pascal Grondin of Glaxo		802;901	
225	GLAX12039-40	12/16/92	Potencies of Various Cyclic Nucleotide and IBMX analogs as Activators of cGMP Defendant Protein Kinases, as Inhibitors of cG-BPDE and as Relaxants of Pig Coronary Arteries			
226	VC000396	12/17/92	Letter from Dr. F. Hyafil of Glaxo to Jackie D. Corbin, Ph.D.		602;802;901	
227	GLAX16329-377	12/21/92	Projet PDE Meeting Agenda and Minutes			

	Bates Number	Date	Description	Identified	Objection	Admitted
228	VU000309-358	12/21/92	English translation of GLAX 16329-77		LP;602;802	
229	GLAX14697	12/23/92	ISIS Print: GF179505X, GF179506X			
230	VC006240-256	1/1/93	Jackie Corbin, Ph.D.'s 1993 Calendar		402;403;901; 802	
231	VC000421-422	2/3/93	Letter from Jackie D. Corbin, Ph.D. to Dr. Pascal Grondin of Glaxo.		802;901	
232	VK001360-1516	1/8/93	Konjeti Notebook		802;901	
233	GLAX02006-8	1/12/93	Letter from Dr. Pascal Grondin of Glaxo to Jackie D. Corbin, Ph.D.			
234	GLAX17320	1/12/93	Compound Data Card GF180811X			
235	GLAX17321	1/12/93	Compound Data Card GF180814X			
236	GLAX14725	1/19/93	ISIS Print: GF180808X, GF180811X			
237	GLAX14726	1/19/93	ISIS Print: GF180814X, GF180817X			
238	GLAX02009-10	1/20/93	Facsimile from Jackie D. Corbin, Ph.D. to Dr. Pascal Grondin of Glaxo			
239	VC000409-410	1/22/93	Letter from Dr. Pascal Grondin of Glaxo to Jackie D. Corbin, Ph.D.			
240	VC000419-420	1/25/93	Letter from Fiona Roberts of Glaxo to Jackie D. Corbin, Ph.D.		402;802;901	
241	GLAX02013	2/1/93	Facsimile from Jackie D. Corbin, Ph.D. to Dr. Pascal Grondin of Glaxo			
242	GLAX02014	2/3/93	Facsimile from Dr. Pascal Grondin of Glaxo to Jackie D. Corbin, Ph.D.			
243	VK000021-22	2/3/93	Letter from Jackie D. Corbin, Ph.D. to Pascal Grondin of Glaxo		802;901	
244	GLAX01998	2/3/93	Letter from Jackie D. Corbin, Ph.D. to Pascal Grondin of Glaxo			
245	GLAX16424-440	2/4/93	Pde V Inhibitors: Azapurinone-Like Series, Beta-Carboline Series			

	Bates Number	Date	Description	Identified	Objection	Admitted
246	GLAX17401	2/11/93	Compound Data Card GF184257X			
247	GLAX17404	2/16/93	Compound Data Card GF184648X			
248	GLAX17405	2/16/93	Compound Data Card GF184654X			
249	GLAX17406	2/16/93	Compound Data Card GF184657X			
250	VC000428	3/1/93	Letter from Dr. F. Hyafil of Glaxo to Jackie D. Corbin, Ph.D.		802;901	
251	GLAX18479	3/4/93	Compound Data Card GF186202A			
252	GLAX18480	3/4/93	Compound Data Card GF186203A			
253	VC000423-424	3/5/93	Letter from Sekhar R. Konjeti to Dr. Pascal Grondin of Glaxo		802;901	
254	GLAX01995	3/9/93	Facsimile from Jackie D. Corbin, Ph.D. to Dr. Pascal Grondin of Glaxo			
255	VC000425	3/9/93	Facsimile from Dr. Pascal Grondin of Glaxo to Jackie D. Corbin, Ph.D.		802;901	
256	VK000143-227	3/19/93	Sekhar Konjeti Notebook		802;901	
257	VC000430-431	4/1/93	Facsimile from Dr. F. Hyafil to Jackie D. Corbin, Ph.D.		802;901	
258	GLAX15248	4/1/93	ISIS Print: GI118611A, GI11815A			
259	GLAX15253	4/1/93	ISIS Print: GI119835X, GI119890A			
260	GLAX15254	4/1/93	ISIS Print: GI119894X, GI120179A			
261	GLAX15266	4/1/93	ISIS Print: GI126072X, GI126923A			
262	GLAX15267	4/1/93	ISIS Print: GI127039X, GI127431A			
263	GLAX15269	4/1/93	ISIS Print: GI128058X, GI128633X			
264	GLAX15272	4/1/93	ISIS Print: GI132723X, GI132724A			
265	VC000433	4/2/93	Letter from Jackie D. Corbin, Ph.D. to Dr. F. Hyafil of Glaxo		403;802;901	

	Bates Number	Date	Description	Identified	Objection	Admitted
266	GLAX13926-937	4/19/93	Lot summaries for GF190126, GF190127, GF190128, GF190129, GF190130, GF190131, GF190133, GF190134, GF190135, GF190136, GF190137, and GF190138			
267	GLAX18484	4/19/93	Compound Data Card GF190128X			
268	GLAX18485	4/19/93	Compound Data Card GF190129X			
269	GLAX18486	4/19/93	Compound Data Card GF190130X			
270	GLAX18487	4/19/93	Compound Data Card GF190131X			
271	GLAX18488	4/19/93	Compound Data Card GF190134X			
272	GLAX17604	4/19/93	Compound Data Card GF190135X			
273	GLAX17605	4/19/93	Compound Data Card GF190133X			
274	GLAX17603	4/19/93	Compound Data Card GF190136X			
275	GLAX17606	4/19/93	Compound Data Card GF190137X			
276	GLAX17607	4/19/93	Compound Data Card GF190138X			
277	GLAX17608	4/19/93	Compound Data Card GF190126X			
278	VC000458	4/22/93	Letter from Fiona Roberts of Glaxo to Jackie D. Corbin, Ph.D.		402;802;901	
279	DEPEX00040 5-452	4/28/93	Projet PDE Meeting Agenda and Minutes		LP;802	
280	VU000360-363	4/28/93	English translation of DEPEX00405-407		LP;802;901;DI	
281	GLAX14839	5/10/93	ISIS Print: GF190126X, GF190127X			
282	GLAX14842	5/10/93	ISIS Print: GF190133X, GF190134X			
283	GLAX14841	5/10/93	ISIS Print: GF190130X, GF190131X			
284	GLAX14843	5/10/93	ISIS Print: GF190135X, GF190136X			
285	GLAX14844	5/10/93	ISIS Print: GF190137X, GF190138X			
286	GLAX14840	5/10/93	ISIS Print GF190128X, GF190129X			

	Bates Number	Date	Description	Identified	Objection	Admitted
287	VC000664	5/27/93	Notice of Receipt		402;403;602; 802;901	
288	GLAX25334-337	6/1/93	Compound diagrams			
289	GLAX25327	6/7/93	Non specific compounds			
290	VC000434	6/9/93	Flight Itinerary		802;901	
291	VC000437	6/13/93	Schedule for Corbin Paris visit		802;901	
292	VC000443	6/18/93	Letter from Jackie D. Corbin, Ph.D. to Dr. Ann Charlotte de Gouville of Glaxo		802;901	
293	GLAX01984	6/18/93	Letter from Jackie D. Corbin, Ph.D. to Dr. Pascal Grondin of Glaxo			
294	VC000440	6/18/93	Letter from Jackie D. Corbin, Ph.D. to Dr. Harvey Coste of Glaxo		802;901	
295	VC000441	6/18/93	Letter from Jackie D. Corbin, Ph.D. to Dr. Jorge Kirilovsky of Glaxo		802;901	
296	VC000442	6/18/93	Letter from Jackie D. Corbin, Ph.D. to Dr. R. Labaudiniere of Glaxo		802;901	
297	GLAX00811	6/18/93	Letter from Jackie D. Corbin, Ph.D. to Dr. F. Hyafil of Glaxo			
298	GLAX01988-989	7/1/93	Letter from Pascal Grondin of Glaxo to Jackie D. Corbin, Ph.D.			
299	GLAX01987	7/8/93	Facsimile from Jackie D. Corbin, Ph.D. to Dr. Pascal Grondin			
300	GLAX01985-986	7/8/93	Facsimile from Dr. Pascal Grondin of Glaxo to Jackie D. Corbin, Ph.D.			
301	GLAX25440	7/8/93	Compound Data Card for GF19696OX			
302	GLAX06969-7180	7/11/93	Myriam Ajakane Notebook			
303	GLAX01983	7/13/93	Letter from Sekhar Konjeti, Ph.D. to Pascal Grondin of Glaxo			

	Bates Number	Date	Description	Identified	Objection	Admitted
304	GLAX14783	7/26/93	ISIS Print: GF186202A, GF186203A		602;802	
305	VK000013-17	7/27/93	Facsimile from Grondin (Glaxo) to Corbin (Vanderbilt) regarding analog comparisons			
306	GLAX17806	7/30/93	Compound Data Card GF196960X			
307	GLAX13603-638	8/6/93	Cecile Bertko Notebook			
308	VK000029-30	8/10/93	Letter from Sekhar R. Konjeti to Dr. Pascal Grondin of Glaxo		802;901	
309	GLAX25342	8/10/93	Potencies of cGMP Analogs as Activators of cG Kinases and cA Kinases			
310	GLAX01981	8/13/93	Letter from Pascal Grondin of Glaxo to Jackie D. Corbin, Ph.D.			
311	GLAX01980	11/10/93	Letter from Pascal Grondin of Glaxo to Jackie D. Corbin, Ph.D.			
312	VK000043	11/15/93	Letter from Sekhar R. Konjeti to Dr. Pascal Grondin of Glaxo		802;901	
313	VC000489	11/22/93	Letter from Jackie D. Corbin, Ph.D. to Dr. Pascal Grondin of Glaxo		402;802;901	
314	VC000494	12/02/93	Letter from Jackie D. Corbin, Ph.D. to Fiona Roberts of Glaxo		402;802;901	
315	VK000052	12/02/93	Letter from Sekhar R. Konjeti to Dr. Pascal Grondin of Glaxo		402;802;901	
316	VK000053	12/02/93	Letter from Sekhar R. Konjeti to Dr. F. Hyafil of Glaxo		402;802;901	
317	VK000049	12/03/93	Facsimile from Fiona Roberts of Glaxo to Jackie D. Corbin, Ph.D.		802;901	
318	VK000046	12/06/93	Letter from Jackie D. Corbin, Ph.D. to Fiona Roberts at Glaxo		402;802;901	
319	VC000496	12/07/93	Facsimile from Fiona Roberts of Glaxo to Jackie D. Corbin, Ph.D.		402;802;901	

	Bates Number	Date	Description	Identified	Objection	Admitted
320	VC000502	12/08/93	Facsimile from Jackie D. Corbin, Ph.D. to Dr. Pascal Grondin of Glaxo			
321	VC000505-7	1/4/94	Letter from Dr. Pascal Grondin of Glaxo to Sekhar R. Konjeti		802;901	
322	VK000059-60	1/7/94	Letter from Sekhar R. Konjeti to Dr. Pascal Grondin of Glaxo		802;901;402	
323	VC000509	1/13/94	Facsimile from Fiona Roberts to Jackie D. Corbin, Ph.D.		402;802;901	
324	VC000508	1/14/94	Letter from Jackie D. Corbin, Ph.D. to Fiona Roberts of Glaxo		402;802;901	
325	GLAX25344-346	1/18/94	Facsimile from Allan Baxter of Glaxo to R. Labaudiniere and F. Hyafil of Glaxo			
326	GLAX25204-236	1/18/94	Hyafil Slide Presentation			
327	VK000057	1/21/94	Facsimile from Fiona Roberts of Glaxo to Jackie D. Corbin, Ph.D.		402;802;901	
328	ICOS000211-215	1/21/94	Request for Grant of a Patent – Title of Invention: Chemical Compounds		106-602;901	
329	VC000525	1/28/94	Facsimile from Dr. Pascal Grondin to Jackie D. Corbin, Ph.D.		402;802;901	
330	GLAX01975	1/31/94	Facsimile from Jackie D. Corbin, Ph.D. to Dr. Pascal Grondin of Glaxo			
331	GLAX01979	2/02/94	Facsimile from Jackie D. Corbin, Ph.D. to Dr. Pascal Grondin of Glaxo			
332	VC000527	2/11/94	Letter from Jackie D. Corbin, Ph.D. to Dr. Pascal Grondin of Glaxo		402;802;901	
333	VC000529	2/24/94	Facsimile from Dr. Pascal Grondin of Glaxo to Jackie D. Corbin, Ph.D.		402;802;901	
334	VK000018	3/21/94	Facsimile from Dr. Pascal Grondin of Glaxo to Jackie D. Corbin, Ph.D.			
335	VK000019	4/5/94	Letter from Sekhar R. Konjeti to Dr. Pascal Grondin of Glaxo		402;802;901	

	Bates Number	Date	Description	Identified	Objection	Admitted
336	GLAX00849	4/14/94	Facsimile from Dr. Pascal Grondin of Glaxo to Sekhar R. Konjeti			
337	GLAX00850	4/19/94	Letter from Dr. Pascal Grondin of Glaxo to Jackie D. Corbin, Ph.D.			
338	GLAX01967, 13182-85	5/9/94	Letter from Pascal Grondin of Glaxo to Dr. Jackie D. Corbin, Ph.D.			
338A	GLAX01971	6/7/94	Letter from Sekhar R. Konjeti to Dr. Pascal Grondin of Glaxo			
339	VC000540	6/23/94	Letter from Pascal Grondin of Glaxo to Dr. Jackie D. Corbin, Ph.D.		402;802;901	
340	GLAX01974	8/16/94	Letter from Jackie D. Corbin, Ph.D. to Dr. Tore Jahnsen of the University of Oslo			
341	VC000545	8/24/94	Letter from Dr. Tore Jahnsen of the University of Oslo to Jackie D. Corbin, Ph.D.		402;802;901	
342	VC000546-47	9/2/94	Facsimile from Urlich Walter, M.D. to Jackie D. Corbin, Ph.D.			
343	VC00548-551	9/5/94	Facsimile from Dr. Pascal Grondin of Glaxo to Jackie D. Corbin, Ph.D.		402;802;901	
344	GLAX01970	9/9/94	Letter and note from Jackie D. Corbin, Ph.D. to Dr. Pascal Grondin of Glaxo			
345	VC000554	9/16/94	Facsimile from Jackie D. Corbin, Ph.D. to Dr. Pascal Grondin of Glaxo		402;802;901	
346	VC000640	9/30/94	Letter from Fiona Roberts of Glaxo to Jackie D. Corbin, Ph.D.		402;802;901	
347	GLAX01973	10/19/94	Letter from Jackie D. Corbin, Ph.D. to Christian Schudt			
348	GLAX01972	10/19/94	Letter from Sekhar R. Konjeti to Dr. Pascal Grondin of Glaxo			
349	VK000002	10/20/94	Facsimile from Dr. Pascal Grondin of Glaxo to Jackie D. Corbin and Sekhar R. Konjeti		402;802;901	

	Bates Number	Date	Description	Identified	Objection	Admitted
350	GLAX10811-812	10/20/94	Letter from Jackie D. Corbin, Ph.D. to Dr. F. Hyafil of Glaxo			
351	GLAX10810	10/28/94	Letter from Dr. F. Hyafil of Glaxo to Jackie D. Corbin, Ph.D.			
352	GLAX10813-814	12/01/94	Letter from Jackie D. Corbin, Ph.D. to Dr. Michael Elves of Glaxo			
353	VC000560	12/07/94	Letter from Dr. Michael Elves of Glaxo to Jackie D. Corbin, Ph.D.		402;802;901	
354		12/20/94	Withdrawn			
355	GLAX01976	12/28/94	Letter from Sekhar R. Konjeti to Dr. Pascal Grondin of Glaxo			
356	ICOS001756-788	1/1/95	Synthesis and Biological Activity of New and Potent 3-Isobutyl-1 Methylxanthine Analogs and cGMP Analogs		403;802;901	
357	GLAX11826-835	1/1/95	PDE V Project Indentification of a Back-Up			
358	GLAX00866-907	1/16/95	Facsimile from Allan Baxter of Glaxo to Dr. F. Hyafil of Glaxo			
359	VC000561	1/19/95	Letter from Dr. Clive A. Halliday of Glaxo to Jackie D. Corbin, Ph.D.		402;901;802	
360	GLAX01977	2/3/95	Letter from Sekhar R. Konjeti to Dr. Pascal Grondin of Glaxo			
361	VK000006	2/21/95	Facsimile from Malcolm Skingle of Glaxo to Jackie D. Corbin, Ph.D.		802;901;402	
362	VK000003-5	2/21/95	Facsimile from Dr. Pascal Grondin of Glaxo to Sekhar R. Konjeti		802;901	
363	GLAX01978	5/15/95	Note from Sekhar R. Konjeti to Pascal Grondin of Glaxo			
364	GLAX09974	5/15/95	Abstract Form for 9th International Conference on Second Messengers & Phosphoproteins--			
365	VC000565	6/21/95	Letter from Jackie D. Corbin, Ph.D. to Dr. Pascal Grondin of Glaxo		402;802;901	

	Bates Number	Date	Description	Identified	Objection	Admitted
366	GLAX00815-826	1/1/96	Design and Synthesis of Xanthines and Cyclic GMP Analogues as Potent Inhibitors of PDE5			
367	ICOS002254-282	1/22/97	Appendix B Compounds Jan 22nd. Provisional List at January 22, 1997		402;602;802; 901;DI	
368	ICOS000886-928	7/29/97	US Patent No. 5,652,131		402;403;802; 901	
369	VC000958-999	12/20/97	US Patent No. 5,702,936		402;403;802; 901	
370		1/12/99	U.S. Patent No. 5,859,006		NP	
371	ICOS000801-842	9/21/99	US Patent No. 5,955,583		402;403;802; 901	
372	ICOS000756-800	3/14/00	U.S. Patent No. 6,037,119		402;403;802; 901	
373		10/31/00	US Patent No. 6,140,329		NP	
374	VC000886-893	9/17/03	The Discovery of Tadalafil: A Novel and Highly Selective PDE5 Inhibitor. 1: 5,6,11, 11a- Tetrahydro-IH-imidazo [1',5': 1,6] pyrido [3,4-b] indole-1,3 (2H)-dione Analogues		402;802;901	
375	VC000894-903	9/17/03	The Discovery of Tadalafil: A Novel and Highly Selective PDE5 Inhibitor. 2: 2,3,6,6,,12,121-hexahydropyrazino [1',2': 1,6] pyrido [3,4-b] indole- 1,4-dione Analogues		402;802;901	
376			Barry Ross Resume		402;DI;NP	
377			Pascal Grondin Resume		402;DI;NP	
378			Notice to Take Deposition Duces Tecum of GlaxoSmithKline		402;602;802	
379	GLAX24571-749	1/1/03	Information Scientifique Enregistrant Produits Commerciaux Through 9/16/9			
380		10/25/06	Vanderbilt's Amended Notice to Take Deposition of ICOS Corporation Designee		402;602;802	

	Bates Number	Date	Description	Identified	Objection	Admitted
381	GLAX26471-474	1/07	Standard Operating Procedure re: requests for samples			
382	VU000364-368	1/07	English translation of GLAX 26471-74		LP;402;602; 802	
383	GLAX18489-19152	1/07	Chembase Manual			
384	GLAX25393-416	1/07	Chembase User Guide (French)			
385	VU000369-393	1/07	English translation of GLAX 25393		LP;602;802	
386	GLAX25456-460	1/07	SOP re: how to do an SOP			
387	GLAX25470-482	1/07	SOP re: Compound Data Cards			
388	VU000394-407	1/07	English translation of GLAX 25470-82		LP;602;802	
389	GLAX25538-548	1/07	SOP re: registering chemical information in the GUS database			
390	VU000408-419	1/07	English translation of GLAX 25538		LP;602;802	
391	GLAX25520-522	1/07	SOP: re maintaining lab notebooks			
392	VU000420-423	1/07	English translation of GLAX 25520-22		LP;602;802	
393	GLAX25549-554	1/07	SOP re: maintaining chemistry lab notebooks			
394	VU000424-430	1/07	English translation of GLAX 25549-54		LP;602;802	
395	GLAX26480-484	1/07	SOP re transfer of information from GUS and CCGC databases			
396	VU000431-436	1/07	English translation of GLAX 26480-84		LP;402;802	
397	GLAX25441-446	1/07	SOP re: CCGC database			

	Bates Number	Date	Description	Identified	Objection	Admitted
398	VU000437-443	1/07	English translation of GLAX 25441-46		LP;402;802	
399	GLAX26475-479	1/07	SOP re: requests for samples			
400	GLAX25483-519	1/07	International SOP re: registration and numbering of chemical substances			
401	GLAX25523-537	1/07	SOP: re registering chemical information in the GUS database/ISISbase			
402	VU000444-459	1/07	English translation of GLAX 25523-37		LP;402;602; 802	
403	GLAX25555-559	1/07	SOP re: maintaining biology lab notebooks			
404	GLAX25465-469		Bon Usage des Procedures			
405	VU000460-465	1/07	English translation of GLAX 25465		LP;602;802	
406	ICOS2193-297		Glaxo/ICOS Collaboration Agreement, As Amended		402;602;802; DI	
407		3/23/07	ICOS's Response to Vanderbilt's Third Set of Interrogatories		602;802	
408		4/17/07	ICOS's Supplemental Response to Vanderbilt's Interrogatory No. 11		602;802	
409		1/3/06	ICOS's Response to Vanderbilt's First Set of Interrogatories (Nos. 1-16)		602	
410		11/14/06	ICOS's Reponses to Vanderbilt's Second Set of Interrogatories (Nos. 17-19)		602;402;403	
411		12/18/06	Opinions of Sekhar R. Konjeti, Ph.D. as Expert Witness, including attachments		802;901	
412		12/15/06	Expert Report of Sharron H. Francis, Ph.D., including exhibits		602;802;901; 106;NP;LP	

	Bates Number	Date	Description	Identified	Objection	Admitted
413		12/1/06	Curriculum Vitae of Peter Anthony Crooks, MSc, PhD, FRPharmS, CSci, CChem, FRSC (Crooks Rept. Attachment)		802;901	
414		12/16/06	Expert Report of Peter A. Crooks, including attachments		802;901	
415		12/18/06	Curriculum Vitae of John T. Koh, Ph.D. (Koh Rept. Attachment)		802	
416		12/18/06	Expert Report of Professor John T. Koh, Ph.D., including attachments		802	
417		12/18/06	Curriculum Vitae of the Honorable Gerald J. Mossinghoff (Mossinghoff Rept. Exh. A)		402:802;901	
418		12/18/06	Expert Report of Gerald J. Mossinghoff, including exhibits		402;403;802; 901;106	
419		12/18/06	Documents listed in List of Documents and Materials Reviewed, (Mossinghoff Rept. Exh. E		106;402;802	

KEY	
FRE 106	Completeness
FRE 402	Relevance
FRE 403	Prejudice or Confusion, cumulative waste of time
FRE 602	Foundation
FRE 802	Hearsay
FRE 901	Authentication
LP	Late Produced Document (See FRCP 37 (c)(1))
NP	Document Not Produced (See FRCP 37(c)(1))
DI	Description of Document Inadequate to Identify